0RC6.LSE Pharma Mar SAU

Healthcare Commercial Services & Supplies London Exchange
74.06 EUR
Close of Nov 3, 2026
62.83 104.12
Market cap
EUR 16.4B
P/E
14.7x
P/B
-
ROE
2.5%
Dividend yield
1.19%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is 0RC6.LSE undervalued?

Graham number

The Graham number of Pharma Mar SAU cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharma Mar SAU fundamental analysis

No fundamental analysis for Pharma Mar SAU yet.

Pharma Mar SAU stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharma Mar SAU

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue…

Full company profile